TG Therapeutics TGTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's net change in cash?
- TG Therapeutics (TGTX) reported net change in cash of $363.07M in Q1 2026.
- How has TG Therapeutics's net change in cash changed year-over-year?
- TG Therapeutics's net change in cash increased by 860.3% year-over-year, from -$47.75M to $363.07M.
- What is the long-term trend for TG Therapeutics's net change in cash?
- Over 2 years (2021 to 2025), TG Therapeutics's net change in cash has grown at a -35.5% compound annual growth rate (CAGR), from -$254.55M to -$105.78M.
- What does net change in cash mean?
- The total change in the company's cash position during the period.
- How do you interpret net change in cash?
- An increase indicates net cash generation, while a decrease indicates net cash consumption, impacting the company's immediate liquidity.
- How does net change in cash compare across companies?
- Standard across all public companies; highly dependent on the current business cycle and capital expenditure plans.